{
    "clinical_study": {
        "@rank": "120965", 
        "arm_group": {
            "arm_group_label": "MRX34", 
            "arm_group_type": "Experimental", 
            "description": "Single agent MRX34"
        }, 
        "brief_summary": {
            "textblock": "This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or\n      those with liver metastasis from other cancers. The drug is given intravenously, twice per\n      week for three weeks in a row and then one week off. Additionally patients with hematologic\n      malignancies will be evaluated on a treatment schedule of five days in a row with two weeks\n      off."
        }, 
        "brief_title": "A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposome Injectable Suspension", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Liver Cancer", 
            "Solid Tumors", 
            "Lymphoma", 
            "AML", 
            "ALL", 
            "CLL", 
            "CML in Accelerated or Blast Phase", 
            "Multiple Myeloma", 
            "MDS"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Blast Crisis", 
                "Liver Neoplasms", 
                "Lymphoma", 
                "Multiple Myeloma", 
                "Neoplasms, Plasma Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a Phase I, open-label, multicenter, dose-escalation study to investigate the safety,\n      Pharmacokinetics and Pharmacodynamics of the micro ribonucleic acid (microRNA) MRX34, in\n      patients with unresectable primary liver cancer or advanced or metastatic cancer with liver\n      involvement or hematologic malignancies.  MRX34 will be administered IV twice a week as a\n      single agent for 3 weeks with 1 week off (total 28 days) or daily x 5 with 2 weeks off\n      (total of 21 days)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Aged \u2265 18 years\n\n          2. Patients with histologically confirmed unresectable primary liver cancer or advanced\n             metastatic cancer with liver metastasis. For the hematologic malignancy cohorts,\n             patients with AML, ALL, CLL, CML in accelerated or blast phase, lymphoma, MM or MDS\n             may be enrolled\n\n          3. Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n\n          4. Acceptable liver function:\n\n               -  Total bilirubin \u2264 1.5 times the upper limit of normal (ULN); for   patients with\n                  hepatocellular carcinoma only, total bilirubin \u2264 3 mg/dL (i.e. Child-Pugh Score\n                  for bilirubin is no greater than 2).\n\n               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline\n                  phosphatase (ALP) \u2264 5 x ULN.\n\n          5. Acceptable renal function:\n\n             \u2022 Serum creatinine \u2264 1.5 times the ULN, or calculated creatinine clearance \u2265 60\n             mL/min/1.73 m2 for patients with creatinine levels above 1.5 times  the institutional\n             normal\n\n          6. Acceptable hematological status:\n\n               -  Absolute Neutrophil Count (ANC) \u2265 1500 cells/mm3\n\n               -  Platelet count \u2265 100,000 plts/mm3 (without transfusion); \u2265 75,000 plts/mm3 for\n                  patients with hepatocellular carcinoma only.  For hematologic malignancy\n                  patients blood counts cited above do not apply\n\n               -  Hemoglobin \u2265 9 g/dL\n\n               -  For the hematologic malignancy patients, blood count values cited above do not\n                  apply.\n\n          7. Prothrombin time (PT) or International Normalized Ratio (INR) \u2264 1.25 x ULN;  for\n             patients with hepatocellular carcinoma only, INR <1.7 or prothrombin time (PT) or < 4\n             seconds above ULN (i.e. Child-Pugh Score is no greater than 1 for the coagulation\n             parameter); for patients with hepatocellular carcinoma only, serum albumin > 2.8 g/dL\n             (i.e. Child-Pugh Score for albumin is no greater than 2). For the hematologic\n             malignancy patients, the coagulation and albumin status cited above do not apply\n\n          8. For patients with hepatocellular carcinoma only, Child-Pugh Class A (score 5-6)\n             disease. Score for hepatic encephalopathy must be 1; the score for ascites must be no\n             greater than 2 and clinically irrelevant; for the determination of the Child-Pugh\n             Class.\n\n        Exclusion Criteria:\n\n          1. New York Heart Association (NYHA) Class III or IV cardiac disease, myocardial\n             infarction within the past 6 months, unstable and/or symptomatic arrhythmia, or\n             evidence of ischemia on ECG.\n\n          2. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic\n             therapy.\n\n          3. Pregnant or nursing women.\n\n          4. Known infection with human immunodeficiency virus (HIV).\n\n          5. Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other\n             conditions) that could compromise protocol objectives in the opinion of the\n             investigator and/or the sponsor.\n\n          6. Patients with recent history of hemorrhage and patients predisposed to hemorrhage due\n             to coagulopathies or structural anomalies.\n\n          7. Patients who require treatment with therapeutic doses of coumarin-type anticoagulants\n             (maximum daily dose of 1mg allowed for port line patency permitted).\n\n          8. Patients with cirrhosis classed as Child-Pugh B or C."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01829971", 
            "org_study_id": "MRX34-101"
        }, 
        "intervention": {
            "arm_group_label": "MRX34", 
            "intervention_name": "MRX34", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "microRNA", 
            "Primary liver cancer"
        ], 
        "lastchanged_date": "April 18, 2014", 
        "location": [
            {
                "contact": {
                    "email": "joschaffer@shc.org", 
                    "last_name": "Joyce Schaffer, MSN RN AOCNS", 
                    "phone": "877-273-3713"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85258"
                    }, 
                    "name": "Virginia G. Piper Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Jasgit Sachdev, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "mcclure.pamela@mayo.edu", 
                    "last_name": "Pamela A McClure", 
                    "phone": "480-301-4963"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259"
                    }, 
                    "name": "Mayo Clinic Arizona"
                }, 
                "investigator": {
                    "last_name": "Mitesh Borad, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "adrian.avila@utsouthwestern.edu", 
                    "last_name": "Adrian Avila", 
                    "phone": "214-648-5107"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "UT Southwestern Medical Center"
                }, 
                "investigator": {
                    "last_name": "Muhammad Beg, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "cwilcox@mdanderson.org", 
                    "last_name": "Cecilia Wilcox"
                }, 
                "contact_backup": {
                    "email": "bwherrick@mdanderson.org", 
                    "last_name": "Brian Herrick"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "investigator": [
                    {
                        "last_name": "David Hong, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jorge Cortes, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "goodwine@uthscsa.edu", 
                    "last_name": "Epp Goodwin", 
                    "phone": "210-450-5798"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Uthscsa/Ctrc"
                }, 
                "investigator": {
                    "last_name": "Andrew Brenner, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposome Injectable Suspension", 
        "overall_official": {
            "affiliation": "UTHSCSA/CTRC", 
            "last_name": "Andrew Brenner, PhD, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Dose-limiting toxicity (DLT) in 3-6 patients at the end of one treatment cycle", 
            "measure": "The maximum tolerated dose (MTD) for MRX34 and the recommended phase 2 dose (RPh2D)", 
            "safety_issue": "Yes", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01829971"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Peak blood concentration and Area Under the Curve (AUC) of MRX34 after IV dosing", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Number of patients with evidence of clinical activity of MRX34", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Mirna Therapeutics, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Cancer Prevention Research Institute of Texas", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Mirna Therapeutics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}